MAC Lung Disease Market Poised for Growth Across the 7MM During the Forecast Period (2025-2034) Amid Rising Prevalence and New Therapeutic Solutions
The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of innovative therapies such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720, among others. Furthermore, the increasing prevalence of MAC lung disease, influenced by host factors like advanced age, COPD, thoracic abnormalities, and environmental exposure to MAC in soil, water, and aerosol-generating activities, is expected to expand the MAC lung disease market potential.
LAS VEGAS, May 20, 2025 /PRNewswire/ — Mycobacterium avium Complex (MAC) refers to a group of bacteria, primarily Mycobacterium avium and Mycobacterium intracellulare, that are responsible for MAC lung disease. Accurate identification typically requires genetic testing. MAC is the leading cause of nontuberculous mycobacterial (NTM) lung infections in the United States and can affect people of all ages, although it is more common in older adults, postmenopausal women, smokers, and individuals with weakened immune systems or pre-existing lung conditions such as bronchiectasis, COPD, cystic fibrosis, emphysema, or a prior history of tuberculosis.
DelveInsight estimates that in 2023, there were around 119K diagnosed prevalent cases of MAC lung disease across the 7MM, with the United States accounting for approximately 64% of these cases. In 2023, there were an estimated 151K diagnosed prevalent cases of NTM lung disease across the 7MM, with the number expected to rise by 2034.
Treatment for MAC lung disease typically involves a combination of multiple antibiotics, most often including a macrolide (such as azithromycin or clarithromycin), a rifamycin (such as rifampin or rifabutin), and ethambutol. This regimen works by inhibiting protein synthesis, disrupting the bacterial cell wall, and preventing replication of the mycobacteria. Therapy generally continues for 12 to 18 months, depending on the severity of the disease and the pathogen's drug susceptibility.
Supportive therapies play an important role, especially for patients with preexisting lung conditions. Chest physiotherapy, mucolytic agents, and bronchodilators help clear mucus and alleviate airway obstruction. Additionally, devices like positive expiratory pressure (PEP) masks and high-frequency chest wall oscillation (HFCWO) devices can assist in reducing bacterial burden.
Learn more about the MAC lung disease treatment @ New Treatment for MAC Lung Disease
ARIKAYCE is the first FDA-approved therapy specifically for MAC lung disease. It is a once-daily inhaled formulation of amikacin, delivered using Insmed's proprietary PULMOVANCE technology to directly target the lungs while reducing systemic exposure. The treatment is administered through the Lamira Nebulizer System and was granted orphan drug status by the FDA in 2013.
In May 2024, new data from the ARISE study were presented at ATS 2024, highlighting outcomes in MAC lung disease patients who had not previously received antibiotic therapy. ARIKAYCE is approved in the US, European Union, and Japan, and is currently being studied in the Phase III ENCORE trial, which focuses on newly diagnosed or relapsed MAC patients who have not begun antibiotic treatment. Topline results from this study are anticipated in the first quarter of 2026.
Find out more on FDA-approved MAC lung disease drugs @ MAC Lung Disease Treatment Options
The scarcity of FDA-approved therapies for MAC lung disease, with only ARIKAYCE being the only approved option, limits treatment options, complicates management of resistant strains, and highlights the need for new therapies.
MannKind Corporation, Janssen Pharmaceutical, and Spero Therapeutics are progressing through various stages of clinical trials, driving innovation in the MAC lung disease market. This activity is creating a dynamic environment, offering significant opportunities for the MAC lung disease market expansion and growth. Among the emerging therapies, MNKD-101, a nebulized formulation of clofazimine, is currently in Phase III clinical development and is expected to launch in the market by 2027.
Discover which therapies are expected to grab major MAC lung disease market share @ MAC Lung Disease Market Report
MNKD-101 is a nebulized formulation of clofazimine being developed to treat severe, chronic, and recurrent lung infections, such as nontuberculous mycobacterial lung disease. This inhaled version is anticipated to provide therapeutic benefits over the existing oral form. MannKind is also working on a dry-powder variant using its proprietary Technosphere platform. In May 2024, the U.S. FDA granted Fast Track Designation to MNKD-101 for NTM lung disease, following its earlier designations as an orphan drug and a Qualified Infectious Disease Product (QIDP).
The FDA approved the Investigational New Drug (IND) application for MNKD-101 in April 2024, paving the way for a Phase III clinical trial. Similarly, Japan's PMDA authorized the Phase III ICoN-1 trial in September 2024, enabling the global trial to move forward.
Bedaquiline fumarate, marketed as SIRTURO, is a diarylquinoline antimycobacterial agent used in combination regimens to treat pulmonary tuberculosis caused by Mycobacterium tuberculosis strains resistant to both rifampin and isoniazid. It is approved for use in adults and children aged 5 years and older, weighing at least 15 kg.
Bedaquiline is currently being studied in a Phase II/III clinical trial as part of a treatment regimen with clarithromycin and ethambutol for adults with treatment-refractory Mycobacterium avium complex lung disease (MAC-LD).
Spero Therapeutics is developing SPR720, an oral therapy for NTM pulmonary disease. SPR720 is a stable prodrug that is rapidly converted into SPR719, which targets the ATPase subunits of gyrase and topoisomerase, mechanisms distinct from fluoroquinolones. Preclinical data have demonstrated SPR720's broad-spectrum activity against key NTM pathogens such as MAC, M. kansasii, and M. abscessus, in both treatment-refractory and treatment-naïve patients. The FDA has granted SPR720 Fast Track status, orphan drug designation, and QIDP designation.
Discover more about drugs for MAC lung disease in development @ MAC Lung Disease Clinical Trials
The anticipated launch of these emerging therapies for MAC lung disease are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the MAC lung disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for MAC lung disease is expected to grow from USD 474 million in the 7MM in 2023 at a significant CAGR by 2034. The market growth across the 7MM is expected to be fueled by the introduction of novel treatments such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720, among others. Additionally, the rising incidence of MAC lung disease driven by factors like aging populations, COPD, structural lung abnormalities, and exposure to MAC through soil, water, and aerosol-generating activities will likely contribute to an expanding MAC lung disease market opportunity.
DelveInsight's latest published market report, titled as MAC Lung Disease Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the MAC lung disease country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The MAC lung disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of NTM Lung Disease
Gender-specific Diagnosed Prevalent Cases of NTM Lung Disease
Species-specific Diagnosed Prevalent Cases of NTM Infection
Total Diagnosed Prevalent Cases of MAC Lung Disease
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM MAC lung disease market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this MAC lung disease market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the MAC lung disease market. Also, stay abreast of the mitigating factors to improve your market position in the MAC lung disease therapeutic space.
Related Reports
Nontuberculous Mycobacterial Infection Market
Nontuberculous Mycobacterial Infection Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NTM infections companies, including AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma, among others.
Nontuberculous Mycobacterial Infection Pipeline
Nontuberculous Mycobacterial Infection Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nontuberculous mycobacterial infection companies, including MannKind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc., Vast Therapeutics, among others.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, among others.
Asthma Market
Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mac-lung-disease-market-poised-for-growth-across-the-7mm-during-the-forecast-period-20252034-amid-rising-prevalence-and-new-therapeutic-solutions–delveinsight-302459926.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Parkview Health patients share heartwarming "thank you" with caregivers in new brand campaign
Patients and their families surprise doctors to express gratitude for life-saving care FORT WAYNE, Ind., June 10, 2025 /PRNewswire/ — Parkview Health today launched its most personal campaign to date: a multi-platform initiative that shares authentic care stories through the lens of Parkview patients. Through a series of heartfelt commercials that will be shared through television, radio, streaming and digital platforms, and more, the campaign aims to showcase the local impact of Parkview's high-quality – and oftentimes life-changing – care. 'This campaign is about trust, connection and elevating the voices of our patients,' said Dena Jacquay, chief administrative officer, Parkview Health. 'As always, the stories we're sharing are genuine, just real people sharing deeply personal moments from their care journey. Their voices capture what healthcare is truly about.' All participants volunteered to share their personal stories of strength and resilience, not only to inspire others in the community, but also to express heartfelt gratitude to their care teams. Each segment shows the emotional moment when a patient or their family member reunites with their provider for the first time since leaving the hospital. As they read letters they've written to their doctors, viewers witness the raw, emotional reactions of caregivers as they hear how much their work meant. Dr. Shamir Haji, Neurocritical Care, Parkview Neurosciences, shared his thoughts on the experience: 'As a neurointensivist, I often meet patients and families at some of the most critical, uncertain moments of their lives. Every decision we make is about giving patients the best possible chance, but rarely do we get to see what comes months after. Hearing a patient or family member read a letter of thanks and realizing the role our team played in their recovery was incredibly humbling. It's a reminder that what we do matters far beyond the ICU.' The campaign stems from Parkview's ongoing commitment to patient-centered care – a focus that earned the health system the 2024 NRC Health Excellence in Patient Experience Award. Insights from hundreds of thousands of patient surveys helped shape the campaign's concept and storytelling approach. 'This series is part of a broader effort to strengthen the connection between Parkview and the families who rely on its care,' Jacquay added, 'especially at a time when trust in healthcare institutions is more important than ever.' In conjunction with patient stories, additional features provide a glimpse into a typical day in the world of Parkview, from co-workers' routines to several patient-provider interactions. 'Over the past few weeks, we shared early previews of the campaign with service line leaders across Parkview,' said Sangeetha Ragavan, vice president of marketing at Parkview. 'Their reactions (including emotional tears) reminded us why this campaign matters. It's not just for the public; it's for every Parkview co-worker. We want our teams to feel proud of the high-quality care and stellar patient experience they provide, and see the difference they make every day.' To hear the patient stories, or submit your own, visit Media contact:Kaitlyn HughesMedia Relations Manager, Parkview | Cell: 574-780-8425 NOTE TO MEDIA: Patient stories will roll out in the coming weeks, further highlighting the impact of Parkview's mission through unscripted, patient-led storytelling. If your outlet is interested in interviewing Parkview providers or patients about their experience, please contact Kaitlyn Hughes. Production stills from campaign videos are attached. Additional photos and video footage are also available upon request.
Malaysian Reserve
15 hours ago
- Malaysian Reserve
Fibroid Surgery Breakthrough: Why LAAM® and DualPortGYN® Are Outperforming Robotic and Open Procedures
Advanced Minimally Invasive Techniques Remove Even the Largest, Most Complex Fibroids ROCKVILLE, Md., June 10, 2025 /PRNewswire/ — Women now have access to a superior alternative for fibroid removal: hyper-specialist surgery that eliminates even the largest and most complex fibroids—without the risks, recovery time, or high costs of robotic, open, or embolization procedures. The Center for Innovative GYN Care (CIGC) is a nationally recognized leader in minimally invasive gynecologic surgery, offering advanced care with unmatched outcomes. 'We see women who've been told their only option is open surgery,' said Dr. Natalya Danilyants, board-certified GYN surgeon and director of CIGC. 'Yet with our advanced techniques, we remove even the largest fibroids through tiny incisions—no required hospital stay, no long recovery. Patients go home the same day and finally get real relief.' CIGC's LAAM® (Laparoscopically Assisted Abdominal Myomectomy) and DualPortGYN® techniques offer unmatched results. Unlike robotic or traditional laparoscopic methods, which are limited by fibroid size or uterine access, CIGC surgeons operate through two tiny incisions, minimizing scarring, complications and preserving fertility. 'Post-surgery my recovery was remarkable,' said a CIGC patient on June 3, 2025. 'Every stage from the initial consultation to my discharge was seamlessly executed.' Another patient was recently prescribed open surgery due to the extremely large size of her fibroids. Instead, she turned to CIGC—and her fibroid was successfully removed through LAAM®. She went home that day, with minimal discomfort, and returned to normal activity within 10 days. No other approach offers: Immediate symptom relief within one hour Fertility preservation by protecting the uterus, cervix, and ovaries Fastest recovery (10–14 days vs. up to 3 weeks for robotic or standard laparoscopic, and up to 8 weeks for open surgery) No hospital stay—performed at our outpatient surgery centers with dedicated care teams in Maryland and New Jersey Many women are offered outdated or unnecessary procedures. Embolization can delay symptom relief and even increase the risk of miscarriage. Robotic and open surgeries involve longer recoveries, more pain, and higher costs. CIGC's approach is the new superior standard for fibroid removal—and it's available now: About The Center for Innovative GYN Care (CIGC) Since 2008, CIGC's board-certified surgeons have delivered advanced, minimally invasive GYN surgery using laparoscopic techniques that result in faster recovery, less pain, and fewer complications. Our procedures are performed at our specialized outpatient centers in Maryland and New Jersey, which provide dedicated nursing teams to each patient, and we participate with many major insurance plans. We welcome patients from across the country and around the world, offering both in-person and virtual consultations. Media Contact: Jasmin Ramseysocial@ 1 888-787-4379, opt 1
Malaysian Reserve
4 days ago
- Malaysian Reserve
NEDHSA to host JiggAerobics event
MONROE, La., June 6, 2025 /PRNewswire/ — Northeast Delta Human Services Authority (NEDHSA) is hosting its seventh JiggAerobics event beginning at 6 p.m. June 12 at Monroe Downtown River Market, 316 S. Grand St. NEDHSA Executive Director Dr. Monteic A. Sizer said the event provides a fun and upbeat activity for individuals of all ages and fitness levels. 'Fitness plays an important role in mental health and, when coupled with proper exercise, is a strong predictor of positive health outcomes,' Dr. Sizer said. 'By hosting events such as JiggAerobics, we are providing an opportunity for citizens of northeast Louisiana to engage in healthy activities and learn about the interconnectedness of their mental and physical health.' The event is part of NEDHSA's #getfitHSA initiative, which supports NEDHSA's integrated care model by increasing access to healthy activities and informing communities about the importance of staying fit and active. Data shows that heart disease, obesity and other physical illnesses are correlated with various forms of trauma, stress and mental illness, Dr. Sizer said. The event will be led by JiggAerobics founder LaDonte Lotts, also known as 'Mr. Get Right.' The dance-based fitness program fuses jigging — an energetic Louisiana dance style — with Lotts' dance moves and numerous plyometric exercises. NEDHSA consistently works to understand the unique health care needs of the citizens of Northeast Louisiana. 'Once we understand the needs and wishes of the people, we actively put programs and services in place to help meet people where they are,' Dr. Sizer said. Register for free tickets at
